Stay updated on Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.

Latest updates to the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page
- Check5 days agoChange DetectedThe revision label on the history page advanced from v3.5.4 to v3.5.5, indicating a minor update to the page's revision metadata.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedA new revision entry (v3.5.4) was added to the study record history, representing an updated submission to the record. The previous revision (v3.5.3) was removed from the visible history.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page’s UI/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3.” This reflects a change in the site’s revision/version rather than a modification to the underlying clinical trial record.SummaryDifference0.1%

- Check55 days agoChange DetectedAdded revision: v3.5.2; removed revision: v3.5.0.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded new sections for Contacts/Locations and Study Status in the record history to reflect updated metadata for the trial.SummaryDifference0.4%

- Check84 days agoChange DetectedRevision v3.5.0 was added to the history and Revision v3.4.3 was removed.SummaryDifference0.1%

Stay in the know with updates to Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.